Loading news...
Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong.
Viking Therapeutics, Inc. (VKTX) reached $36.01 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss drugs. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade.
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
A maintenance study could shed light on the tolerability of VK2735's oral formulation in 2026, ahead of the Phase 3 trial's conclusion. Viking Therapeutics has two Phase 3 trials in process for the subcutaneous VK2735 formulation.
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is.
Viking Therapeutics, Inc. (VKTX) closed at $31.51 in the latest trading session, marking a -1.96% move from the prior day.
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: Leerink Partners Global Healthcare Conference 2026 Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m.
Viking Therapeutics, Inc. (VKTX) reached $33.84 at the closing of the latest trading day, reflecting a +2.64% change compared to its last close.
The pharmaceutical industry is currently witnessing a historic gold rush surrounding obesity treatments. While industry titans like Novo Nordisk NYSE: NVO and Eli Lilly NYSE: LLY dominate the headlines and the pharmacy shelves, the market remains hungry for a third player to disrupt the status quo.
Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regulatory hurdles.
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro brands.
Novo Nordisk's weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.
Viking Therapeutics aims to enter the billion-dollar weight loss drug market. The company is studying a candidate in a phase 3 trial.
Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.
Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid.
Viking should have plenty of news to share with investors this year.
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.